Trial Profile
A Prospective obsERvational Study to asSEss the Effectiveness of Intravitreal Aflibercept Injection in roUtine Clinical Practice in Treatment Naive patientS With Wet Age-related Macular Degeneration in Greece
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PERSEUS-GR
- Sponsors Bayer
- 08 Jan 2020 Status changed from active, no longer recruiting to completed.
- 08 Oct 2019 Planned End Date changed from 30 Sep 2019 to 30 Nov 2019.
- 08 Nov 2018 Planned primary completion date changed from 30 Sep 2019 to 30 Jun 2019.